Characterization of protein–ligand binding interactions of enoyl‐ACP reductase (FabI) by native MS reveals allosteric effects of coenzymes and the inhibitor triclosan

The enzyme enoyl‐ACP reductase (also called FabI in bacteria) is an essential member of the fatty acid synthase II pathway in plants and bacteria. This enzyme is the target of the antibacterial drug triclosan and has been the subject of extensive studies for the past 20 years. Despite the large numb...

Full description

Saved in:
Bibliographic Details
Published inProtein science Vol. 31; no. 3; pp. 568 - 579
Main Authors Joyner, P. Matthew, Tran, Denise P., Zenaidee, Muhammad A., Loo, Joseph A.
Format Journal Article
LanguageEnglish
Published Hoboken, USA John Wiley & Sons, Inc 01.03.2022
Wiley Subscription Services, Inc
Wiley Blackwell (John Wiley & Sons)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The enzyme enoyl‐ACP reductase (also called FabI in bacteria) is an essential member of the fatty acid synthase II pathway in plants and bacteria. This enzyme is the target of the antibacterial drug triclosan and has been the subject of extensive studies for the past 20 years. Despite the large number of reports describing the biochemistry of this enzyme, there have been no studies that provided direct observation of the protein and its various ligands. Here we describe the use of native MS to characterize the protein–ligand interactions of FabI with its coenzymes NAD+ and NADH and with the inhibitor triclosan. Measurements of the gas‐phase affinities of the enzyme for these ligands yielded values that are in close agreement with solution‐phase affinity measurements. Additionally, FabI is a homotetramer and we were able to measure the affinity of each subunit for each coenzyme, which revealed that both coenzymes exhibit a positive homotropic allosteric effect. An allosteric effect was also observed in association with the inhibitor triclosan. These observations provide new insights into this well‐studied enzyme and suggest that there may still be gaps in the existing mechanistic models that explain FabI inhibition.
Bibliography:Funding information
National Institutes of Health, Grant/Award Numbers: R01GM103479, S10OD018504; U.S. Department of Energy, Grant/Award Number: DE‐FC02‐02ER63421
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
USDOE
DE‐FC02‐02ER63421
Funding information National Institutes of Health, Grant/Award Numbers: R01GM103479, S10OD018504; U.S. Department of Energy, Grant/Award Number: DE‐FC02‐02ER63421
ISSN:0961-8368
1469-896X
1469-896X
DOI:10.1002/pro.4252